News Release
For immediate release
April 19, 2006
New Study
Confirms Safety of
5-LOXIN®
AKBA, a natural anti-inflammatory
Morristown,
NJ.........................................................................................
April
19, 2006
A
study
published in this month’s issue of
Toxicology Mechanisms and
Methods demonstrated 5-LOXIN’s broad spectrum of safety.
5-LOXIN is a standardized extract of boswellia serrata, a plant
used traditionally in Indian Ayurvedic Medicine to inhibit
inflammation.
The gum
resin of boswellia serrata contains boswellic acids which are
well recognized for safe and effective use in humans. Among the
boswellic acids, acetyl-keto-beta boswellic acid (AKBA) has been
identified as the most potent inhibitor of mediators of
inflammation. 5-LOXIN’s patent-pending manufacturing process
provides a standardized 30% AKBA content, the highest
commercially available.
In this
study, 5-LOXIN was evaluated for acute oral, acute dermal,
primary skin and eye irritation, and dose-dependent 90-day
subchronic toxicity. In all cases the results conclusively
demonstrated a broad spectrum of safety.
According to
PLT President Paul Flowerman, “This is an important study
affirming 5-LOXIN’s safety in several models.” He continued,
“These results are also supported by a recent Ames mutagenicity
study, further developing the body of evidence supporting its
use.”
In
previously published in vitro and in vivo studies, 5-LOXIN’s
efficacy has been shown. 5-LOXIN inhibits the inflammatory
enzyme called 5-lipoxygenase (5-LOX). While not as well
recognized as the COX-2 enzyme, it plays a significant role in
the expression of inflammation by acting against leukotriene
biosynthesis and the expression of the inflammatory mediators
I-CAM and V-CAM. 5-LOXIN further has been shown to inhibit MMPs,
enzymes that selectively break down connective tissues such as
joint cartilage.
Boswellia
serrata (frankincense) has been used in traditional Ayurvedic
medicine for treatment of inflammation since antiquity, and has
been supported clinically. For example, a recent randomized
double-blind placebo-controlled study of boswellia in 30
patients for 8 weeks reported significant decrease in knee pain,
increased knee flexion, and increased walking distance. The
frequency of swelling in the knee joint was also decreased.
PL Thomas
offers 5-LOXIN internationally in strategic alliance with Laila
Nutraceuticals, India.
Laila
Nutraceuticals is a leader in process development for
standardized herbal extracts and phytochemicals. Laila is a
primary manufacturer of these technologies, and supports this
work with patents and publications.
PLT
has 50 years experience supplying high quality raw materials
from around the world and delivers customized solutions to the
Food, Nutraceutical and Cosmeceutical industries.
For more
information, please contact Eric Anderson at
eric@plthomas.com.
A s
# # #
|
